Future of IBD Testing: Growth Outlook Through 2034

 

The global In-vitro Inflammatory Bowel Disease (IBD) Diagnostics Market is poised for substantial growth over the next decade, projected to expand from US$ 1.6 Bn in 2023 to over US$ 2.9 Bn by 2034, at a steady CAGR of 5.6% during the forecast period 2024–2034. This growth is primarily driven by rising global incidence of Crohn’s disease and ulcerative colitis, improved diagnostic technologies, and the increasing demand for personalized and non-invasive testing solutions.

 

Market Overview: Inflammatory Bowel Disease, comprising primarily Crohn’s disease and ulcerative colitis, remains a persistent global healthcare challenge due to its chronic nature and debilitating symptoms. Accurate and early diagnosis is critical for disease management, making in-vitro diagnostics (IVD) essential in guiding treatment plans and monitoring disease progression. The surge in laboratory-based and molecular testing methods has contributed to the rapid evolution of this sector.

 

Market Drivers & Trends

The market is fueled by key trends and drivers, notably the development of novel biomarkers, the increasing use of non-invasive testing, and the adoption of point-of-care diagnostics (POCT). Conventional methods such as endoscopy are being gradually supplemented or replaced by less invasive and more efficient diagnostic tools, including fecal biomarkers and molecular assays like PCR and NGS.

The growing prevalence of IBD across both developed and developing regions is pushing the demand for early, accessible, and accurate diagnostics. Additionally, artificial intelligence (AI) and machine learning (ML) are increasingly being integrated into diagnostic platforms, enhancing the analytical power of IVD systems and offering personalized insights based on patient-specific genetic and microbiome data.

 

Latest Market Trends

• Companion Diagnostics: Tailored diagnostics to complement personalized treatment regimens are on the rise, particularly for biologic therapies.
• Fecal Biomarkers: Tools like calprotectin, CRP, FIT, and Lactoferrin are revolutionizing IBD testing due to their high specificity and ease of collection.
• Lab Automation: High-throughput diagnostic laboratories employing automated analyzers are improving result turnaround and reliability.
• Point-of-Care Testing (POCT): Increasing use of POCT is enabling decentralized testing, improving access, especially in resource-limited settings.

 

Key Players and Industry Leaders

Several prominent players dominate the global IBD diagnostics market:

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Abbott
• SENTINEL Diagnostic
• BTNX, Inc.
• Immundiagnostik AG
• Quest Diagnostics
• Sysmex SE
• DiaSorin S.p.A
• Biosystems S.A.
• Quidel Corporation
• Eiken Chemical Co., Ltd.

These companies are actively pursuing R&D, product launches, and strategic partnerships to expand their diagnostic capabilities and market reach.

 

Recent Developments

• October 2021: Roche signed a definitive acquisition agreement with Telavant for RVT-3101, a novel TL1A-directed antibody aimed at treating IBD. This move solidifies Roche’s position in targeted therapy for gastrointestinal conditions.
• June 2022: SENTINEL Diagnostics introduced the SENTiFIT 800 Analyzer, specifically designed for automated fecal immunochemical testing (FIT), optimizing colorectal and IBD screening workflows.

These innovations underscore the industry's commitment to technological advancement and expanded diagnostic access.

 

Market New Opportunities and Challenges

The expanding demand for early diagnosis, patient-centric treatment, and companion diagnostics presents lucrative opportunities for IVD developers. Growth prospects are particularly notable in Asia-Pacific, Latin America, and parts of the Middle East & Africa, where rising IBD awareness and infrastructure development are stimulating market expansion.

However, challenges remain. These include the high cost of advanced diagnostic platforms, limited access in rural regions, and the need for skilled healthcare professionals to interpret complex diagnostic data. Overcoming these obstacles will be key to tapping into underserved markets.

 

Gain a preview of important insights from our Report in this sample

 

Future Outlook

The future of the in-vitro IBD diagnostics market is promising. Advances in biomarker discovery, AI-powered diagnostic analytics, and wearable and remote testing devices will shape the next generation of IBD diagnostics. The focus will increasingly shift from reactive to preventive and predictive care, enabling clinicians to diagnose earlier, treat more effectively, and monitor more accurately.

The integration of multi-omics technologies, including genomics, proteomics, and metabolomics, is likely to play a crucial role in early IBD detection and prognosis, fostering a shift toward precision medicine in gastroenterology.

 

Market Segmentation

By Product:

• Assays/Biomarker
• Calprotectin
• Lactoferrin
• Bile Acids
• H. pylori SA
• Pancreatic Elastase
• Others
• Analyzers

By Testing Type:

• Laboratory-based Testing
• Point-of-Care (POC) Testing
• Self-testing Kits

By End-user:

• Diagnostic Laboratories
• Hospitals
• Others (Homecare Testing & Research Institutes)

The laboratory-based testing segment dominates the market due to high accuracy, broad application range, and established clinical reliability. Meanwhile, diagnostic laboratories account for the largest share among end-users owing to their advanced infrastructure and wide availability of specialized testing panels.

 

Regional Insights

North America leads the global in-vitro IBD diagnostics market, owing to:

• High prevalence of IBD
• Advanced diagnostic infrastructure
• Heavy R&D investment
• Presence of key market players

Europe follows closely due to supportive healthcare policies, widespread adoption of non-invasive diagnostic technologies, and aging population. Emerging markets in Asia Pacific—especially China, India, and Japan—are witnessing rapid market growth due to increasing healthcare access and awareness campaigns.

 

Why Buy This Report?

• Comprehensive Market Insights: In-depth analysis of market dynamics, segmentation, and regional trends
• Competitive Landscape: Profiles of major players with strategic developments and financials
• Future-Proof Analysis: Forecasts through 2034 with actionable insights for investors, healthcare providers, and manufacturers
• Innovation Tracking: Up-to-date with latest technological breakthroughs and biomarker discoveries
• Customized Segmentation: Detailed breakdown by product, test type, and end-user for strategic planning

 

Explore Latest Research Reports by Transparency Market Research:

Microbiology Culture Market: https://www.transparencymarketresearch.com/microbiology-culture-market.html

Non-invasive Prenatal Testing Market: https://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html

Medical Radioisotopes Market: https://www.transparencymarketresearch.com/medical-radioisotopes-market.html

Syphilis Immunoassay Diagnostics Market: https://www.transparencymarketresearch.com/syphilis-diagnostics-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com